Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

REGNRegeneron PharmaceuticalsRunning, no new patients

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Non-small Cell Lung Cancer · Hepatocellular Carcinoma · Head and Neck Squamous Cell Carcinoma

15Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Mar 2025, none posted yet

    Counts until it's fixed

    +10

  • 5 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.8
Worry score15

Score over time

Stage
Phase 2
Patients
65 (final count)
Started
Jul 23, 2019
Main results expected
Mar 31, 2025
Fully finished
May 14, 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Major pathologic response (MPR) at time of surgery for the NSCLC cohorts

    Measured over: At time of surgery

  • Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohorts

    Measured over: At time of surgery

  • Major treatment effect (MTE) at time of surgery is the primary endpoint for the HNSCC cohort

    Measured over: At time of surgery

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-03-31, no fading
  • insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT03916627 · record last updated 2026-04-06 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT03916627) ↗